Digest Network Come funziona
Network
/
Società
No
Non verificato

Novocure

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

61 comunicati stampa

Guarda tutti i comunicati
09/11/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Fonte
Novocure
Emittente
Business Wire
1.00
0
29/10/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Farmaceutica
Salute
Oncologia
Medicina - Varie
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Fonte
Novocure
Emittente
Business Wire
1.00
0
28/10/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Fonte
Novocure
Emittente
Business Wire
1.00
0
01/10/2026
Industria
Scienza
Biotecnologia
Oncologia
Salute
Attrezzature medico-sanitarie
Medicina - Varie
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Fonte
Novocure
Emittente
Business Wire
1.00
0
01/10/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Farmaceutica
Salute
Oncologia
Medicina - Varie
Novocure to Report Third Quarter 2026 Financial Results
Fonte
Novocure
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Farmaceutica
Salute
Oncologia
Medicina - Varie
Novocure Announces Upcoming Investor Events
Fonte
Novocure
Emittente
Business Wire
1.00
0
23/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Oncologia
Attrezzature medico-sanitarie
Novocure Reports Second Quarter 2026 Financial Results
Fonte
Novocure
Emittente
Business Wire
1.00
0
01/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Farmaceutica
Salute
Oncologia
Medicina - Varie
Novocure to Report Second Quarter 2026 Financial Results
Fonte
Novocure
Emittente
Business Wire
1.00
0
30/06/2026
Industria
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
Fonte
Novocure
Emittente
Business Wire
1.00
0
18/06/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Fonte
Novocure
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0